ES2103274T3 - Metodo de produccion de proteinas de fusion. - Google Patents
Metodo de produccion de proteinas de fusion.Info
- Publication number
- ES2103274T3 ES2103274T3 ES90913419T ES90913419T ES2103274T3 ES 2103274 T3 ES2103274 T3 ES 2103274T3 ES 90913419 T ES90913419 T ES 90913419T ES 90913419 T ES90913419 T ES 90913419T ES 2103274 T3 ES2103274 T3 ES 2103274T3
- Authority
- ES
- Spain
- Prior art keywords
- dna sequence
- place
- union
- restriction
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
LA INVENCION SE REFIERE A METODOS PARA PRODUCIR PROTEINAS DE FUSION COMPRENDIENDO ESTAS ACTIVIDADES BIOLOGICAS DUALES. ESTOS METODOS COMPRENDEN LA PROVISION DE UNA PRIMERA Y DE SEGUNDA SECUENCIA DE ADN QUE CODIFICAN UN PRIMER Y UN SEGUNDO POLIPEPTIDO, RESPECTIVAMENTE, LA DIGESTION DE LA PRIMERA SECUENCIA DE ADN EN UN LUGAR DE RESTRICCION ADYACENTE DE SU TERMINO 3'' O 5'', Y LA LIGADURA DE UNA SECUENCIA ADAPTADORA/ENLAZADORA (1/A) EN EL EXTREMO FINAL DE LA PRIMERA SECUENCIA DE ADN, FORMANDO ASI UN CASET. LA 1/A COMPRENDE, EN UN EXTREMO, ESA PARTE DE LA PRIMERA SECUENCIA DE ADN QUE SE EXTIENDE DESDE UN TERMINO MAS CERCANO DEL LUGAR DE RESTRICCION HASTA EL LUGAR DE RESTRICCION, Y EN EL OTRO EXTREMO, UN LADO DE UN LUGAR DE UNION. UNA CELULA HUESPED EUCARIOTICA SE MODIFICA CON LA CASET Y LA SEGUNDA SECUENCIA DE ADN QUE TIENE, EN UN EXTREMO, UN LADO DE SITIO DE UNION COMPATIBLE CON EL LADO DEL SITIO DE UNION COMPATIBLE CON EL LADO DEL SITIO DE UNION EN LA 1/A. LA CELULA HUESPED MODIFICA ES CULTIVADA PARA EXPRESAR EL ADN MODIFICADO COMO UNA PROTEINA DE FUSION DE CADENA SENCILLA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40988989A | 1989-09-20 | 1989-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2103274T3 true ES2103274T3 (es) | 1997-09-16 |
Family
ID=23622388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96113414T Expired - Lifetime ES2187598T3 (es) | 1989-09-20 | 1990-08-01 | Metodos para producir proteinas de fusion. |
| ES90913419T Expired - Lifetime ES2103274T3 (es) | 1989-09-20 | 1990-08-01 | Metodo de produccion de proteinas de fusion. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96113414T Expired - Lifetime ES2187598T3 (es) | 1989-09-20 | 1990-08-01 | Metodos para producir proteinas de fusion. |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0765937B1 (es) |
| JP (1) | JP3051162B2 (es) |
| AT (2) | ATE228566T1 (es) |
| AU (1) | AU633357B2 (es) |
| CA (1) | CA2066612C (es) |
| DE (2) | DE69034022T2 (es) |
| DK (2) | DK0765937T3 (es) |
| ES (2) | ES2187598T3 (es) |
| WO (1) | WO1991004329A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| CA2094495C (en) * | 1990-10-22 | 2007-04-03 | David Botstein | Methods for modifying and detecting the effects on the interaction of modified polypeptides and target substrates |
| US5525491A (en) * | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2128511C (en) * | 1992-01-23 | 2006-11-07 | Andreas Pluckthun | Monomeric and dimeric antibody-fragment fusion proteins |
| US6103521A (en) * | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| DE60025829T2 (de) * | 1999-07-12 | 2006-11-02 | Genentech, Inc., South San Francisco | Expressionsvektoren und anwendungsmethoden |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| CZ2003214A3 (cs) | 2000-06-29 | 2003-08-13 | Merck Patent Gmbh | Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| DK1366067T3 (da) * | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| BR0209177A (pt) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| KR101163424B1 (ko) | 2003-12-30 | 2012-07-13 | 메르크 파텐트 게엠베하 | Il-7 융합 단백질 |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| AU2006272555B2 (en) | 2005-07-25 | 2012-03-08 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| SI1966238T1 (sl) | 2005-12-30 | 2012-08-31 | Merck Patent Gmbh | Variante interlevkina-12P40 z izboljšano stabilnostjo |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US10071748B2 (en) | 2015-09-17 | 2018-09-11 | Sony Corporation | System and method for providing driving assistance to safely overtake a vehicle |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN110592057B (zh) * | 2019-09-27 | 2022-01-28 | 昆明理工大学 | 嵌合裂解酶ILTphg和编码此酶的多核苷酸 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4771002A (en) * | 1984-02-24 | 1988-09-13 | Lubrizol Genetics, Inc. | Transcription in plants and bacteria |
-
1990
- 1990-08-01 DE DE69034022T patent/DE69034022T2/de not_active Expired - Fee Related
- 1990-08-01 JP JP2512474A patent/JP3051162B2/ja not_active Expired - Fee Related
- 1990-08-01 AU AU63352/90A patent/AU633357B2/en not_active Ceased
- 1990-08-01 AT AT96113414T patent/ATE228566T1/de not_active IP Right Cessation
- 1990-08-01 ES ES96113414T patent/ES2187598T3/es not_active Expired - Lifetime
- 1990-08-01 DE DE69030579T patent/DE69030579T2/de not_active Expired - Fee Related
- 1990-08-01 CA CA002066612A patent/CA2066612C/en not_active Expired - Lifetime
- 1990-08-01 DK DK96113414T patent/DK0765937T3/da active
- 1990-08-01 WO PCT/US1990/004301 patent/WO1991004329A1/en not_active Ceased
- 1990-08-01 AT AT90913419T patent/ATE152174T1/de not_active IP Right Cessation
- 1990-08-01 DK DK90913419.9T patent/DK0493418T3/da active
- 1990-08-01 EP EP96113414A patent/EP0765937B1/en not_active Expired - Lifetime
- 1990-08-01 ES ES90913419T patent/ES2103274T3/es not_active Expired - Lifetime
- 1990-08-01 EP EP90913419A patent/EP0493418B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991004329A1 (en) | 1991-04-04 |
| ATE228566T1 (de) | 2002-12-15 |
| ATE152174T1 (de) | 1997-05-15 |
| ES2187598T3 (es) | 2003-06-16 |
| CA2066612C (en) | 1998-12-08 |
| DE69034022D1 (de) | 2003-01-09 |
| DE69030579T2 (de) | 1997-11-13 |
| DK0493418T3 (da) | 1997-11-03 |
| EP0493418B1 (en) | 1997-04-23 |
| AU633357B2 (en) | 1993-01-28 |
| EP0765937B1 (en) | 2002-11-27 |
| CA2066612A1 (en) | 1991-03-21 |
| EP0493418A4 (en) | 1992-09-02 |
| JP3051162B2 (ja) | 2000-06-12 |
| AU6335290A (en) | 1991-04-18 |
| EP0493418A1 (en) | 1992-07-08 |
| JPH05500310A (ja) | 1993-01-28 |
| EP0765937A1 (en) | 1997-04-02 |
| DE69034022T2 (de) | 2003-07-10 |
| DE69030579D1 (de) | 1997-05-28 |
| DK0765937T3 (da) | 2003-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2187598T3 (es) | Metodos para producir proteinas de fusion. | |
| FI920923A0 (fi) | Fusionsproteiner, deras framstaellning samt anvaendning. | |
| ES2072900T3 (es) | Expresion elevada de proteinas en levadura. | |
| DK161015C (da) | Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop | |
| ES2046462T3 (es) | Marcadores de activacion de celulas "t". | |
| ATE132902T1 (de) | Humane mangan-superoxiddismutase (hmn-sod) | |
| GR880100198A (el) | Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου. | |
| ES2077666T3 (es) | Proteina de union a fibronectina y su preparacion. | |
| AR024318A1 (es) | Moleculas de acido nucleico del trigo, celulas de plantas transgenicas y plantas y el uso de las mismas para la produccion de almidon modificado. | |
| ES2163864T3 (es) | Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas. | |
| AR006250A1 (es) | Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico | |
| ATE295416T1 (de) | Humanisiertes grünes-fluoreszenzprotein und methoden | |
| CR6538A (es) | Anticuerpos de humano, anti-avb3 recombinantes, acidos nucleicos que codifican a los mismos y metodo de uso | |
| BR9808769A (pt) | Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio | |
| ATE232237T1 (de) | Herstellung von funktionellen, menschlichen urokinaseproteinen | |
| ES8800267A1 (es) | Un metodo para obtener un peptido biologicamente activo que tiene afinidad para un ligando proteinaceo o su receptor | |
| ES2073735T3 (es) | Nuevos analogos de la cadena b del factor de crecimiento derivado de plaquetas y metodo para su produccion homogenea. | |
| ES2196082T3 (es) | Analagos del factor de crecimiento de queratinocitos. | |
| ES2063370T3 (es) | Agentes mejorados para el control biologico de insectos y metodos de uso. | |
| ES2144399T3 (es) | Clonado del adn de virus de anemia de los pollos. | |
| ES2104596T3 (es) | Nuevos polipeptidos, secuencias de adn que permiten su expresion, metodo de preparacion, y utilizacion. | |
| BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
| ES2026206T3 (es) | Procedimiento para mejorar la expresion de proteina de eucariota. | |
| AR016436A1 (es) | Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades | |
| ES2072868T3 (es) | Proteina capaz de unir la fibronectina y su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 493418 Country of ref document: ES |